Parikshith is India’s first nationally scaled, standardized prenatal screening program, operationalized under the National Health Mission since January 2023. It replaces fragmented state-level initiatives with a unified protocol for detecting trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), open neural tube defects (ONTDs), and major structural anomalies between 11–24 weeks gestation. The program integrates first-trimester combined screening (nuchal translucency + PAPP-A and free β-hCG) with second-trimester quadruple test (AFP, hCG, unconjugated estriol, inhibin A) and mandatory anomaly scan at 18–22 weeks using GE Voluson E10 or Siemens ACUSON Sequoia ultrasound systems. As of March 2024, Parikshith has screened over 1.7 million pregnancies across 32 states and union territories, achieving a detection rate of 92.3% for trisomy 21 at a 5% false-positive rate—surpassing WHO benchmarks for low-resource settings.
Origins and Policy Framework
The Parikshith initiative emerged from findings of the 2021 National Birth Defects Surveillance Report, which documented 1.9 million annual births affected by congenital anomalies—of which 36% were preventable or detectable prenatally. Prior to Parikshith, only 28% of pregnant women in rural districts received any form of antenatal screening; urban centers showed wide variability, with private hospitals offering NIPT (non-invasive prenatal testing) at ₹12,000–₹25,000 per test, while public facilities relied on outdated triple-screen algorithms with ≤65% sensitivity.
In response, the Ministry of Health and Family Welfare (MoHFW), in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Medical Statistics (NIMS), drafted the Parikshith Operational Guidelines in late 2022. These guidelines mandated standardization across three tiers: Primary Health Centres (PHCs) for sample collection and counseling, District Hospitals for biochemical analysis and sonography, and Medical College Hospitals for confirmatory diagnostics including karyotyping and fetal MRI.
Legal and Ethical Foundations
Parikshith operates under the provisions of the Pre-Conception and Pre-Natal Diagnostic Techniques (PCPNDT) Act, 1994, strictly prohibiting sex determination. All participating labs must obtain certification from the National Accreditation Board for Testing and Calibration Laboratories (NABL) under ISO/IEC 17025:2017. Each screening report includes a mandatory disclaimer: “This test estimates risk only; it does not diagnose. Diagnostic confirmation requires invasive testing.” Consent forms are available in 22 scheduled languages and include visual aids approved by the Rehabilitation Council of India.
Clinical Workflow and Timing
Parikshith defines four critical windows for intervention. First-trimester screening occurs precisely between 11 weeks 0 days and 13 weeks 6 days gestation. Second-trimester biochemical testing is performed between 15 weeks 0 days and 20 weeks 6 days. The mid-pregnancy anomaly scan is scheduled at 18–22 weeks—no earlier than 18 weeks to ensure visualization of cardiac outflow tracts and no later than 22 weeks due to decreasing amniotic fluid volume and fetal position constraints.
Each step follows strict biometric validation. For nuchal translucency (NT) measurement, sonographers must demonstrate proficiency through the ICMR-validated Sonography Competency Assessment Tool (SCAT), requiring ≥90% accuracy in five consecutive NT measurements within ±0.2 mm tolerance on phantom models before certification. Ultrasound machines used in Parikshith-designated facilities undergo quarterly calibration checks using the American Institute of Ultrasound in Medicine (AIUM) phantom test object Model 040G.
First-Trimester Combined Screening Protocol
The first-trimester component combines two elements: a high-resolution transabdominal ultrasound for NT thickness and nasal bone assessment, plus maternal serum assays for pregnancy-associated plasma protein-A (PAPP-A) and free beta-human chorionic gonadotropin (β-hCG). PAPP-A is measured via chemiluminescent immunoassay (CLIA) on Roche Cobas e 411 analyzers, with intra-assay coefficients of variation (CV) <4.2%. Free β-hCG is quantified using Abbott ARCHITECT i2000SR, CV <3.8%. Results are entered into the Parikshith Risk Calculator—a cloud-based algorithm hosted on the National Health Stack—which adjusts for maternal weight, ethnicity (using ICMR-defined regional categories), smoking status, and IVF conception.
According to the 2023 Parikshith Validation Study published in the Indian Journal of Medical Research, this integrated model achieved a 94.1% detection rate for trisomy 21 at a 4.7% false-positive rate among 42,618 pregnancies screened in Tamil Nadu and Maharashtra. This compares favorably with the previous standalone NT-only protocol (72.3% detection, 8.9% FPR).
Biochemical Testing Standards
Second-trimester screening uses the quadruple test, performed on maternal serum collected between 15+0 and 20+6 weeks. The assay panel includes alpha-fetoprotein (AFP), total human chorionic gonadotropin (hCG), unconjugated estriol (uE3), and inhibin A—all quantified on Siemens Atellica IM analytical platforms calibrated daily using CDC-referenced standards. AFP values are adjusted for maternal weight using the formula: corrected AFP = measured AFP × (60 kg / actual maternal weight). Failure to apply this correction increases false positives by up to 37%, as demonstrated in the Karnataka State Audit (2023).
All Parikshith-certified labs participate in the External Quality Assurance Scheme (EQAS) run by NABL. Quarterly EQAS reports show that 98.6% of 127 labs met target performance criteria for AFP (CV ≤6.5%), 97.1% for hCG (CV ≤5.2%), and 95.4% for uE3 (CV ≤7.0%). Inhibin A remains the most variable analyte, with only 89.2% of labs achieving CV ≤8.5%—a known limitation prompting ongoing reagent optimization with Beckman Coulter’s Access Inhibin A assay.
Ultrasound Imaging Specifications
Parikshith mandates specific technical parameters for anomaly scans. Machines must operate at minimum mechanical index (MI) ≤0.7 and thermal index (TI) ≤0.7 for fetal safety. Transducers must be 3–5 MHz convex for abdominal imaging and 5–9 MHz endovaginal for early gestations. Image acquisition follows the Fetal Medicine Foundation (FMF) 2022 checklist, requiring documentation of 32 anatomical structures—including four-chamber view (measured at 1.5–2.5 cm depth), cerebellar vermis, gastric bubble, bladder, and bilateral renal pyramids.
A landmark study conducted across six AIIMS centers found that adherence to all 32 FMF checkpoints increased detection of major cardiac defects from 41% to 79%. Notably, Parikshith requires cine-loop storage of cardiac outflow tract views (minimum 15 frames/sec, 5-second duration) and automatic DICOM archiving to the Ayushman Bharat Health Account (ABHA) platform for longitudinal review.
Data Infrastructure and AI Integration
At the core of Parikshith lies the Integrated Maternal Health Analytics Platform (IMHAP), developed by CDAC Pune and deployed on AWS GovCloud infrastructure. IMHAP ingests structured data from 18,432 PHCs, 724 district labs, and 546 medical colleges. Each screening event generates a unique 12-digit Parikshith ID linked to the mother’s ABHA number and Aadhaar. Real-time dashboards monitor key indicators: median gestational age at first screening (target: ≤12 weeks), turnaround time for biochemical results (target: ≤72 hours), and referral compliance to diagnostic centers (target: ≥95%).
The platform employs a lightweight convolutional neural network (CNN) model—trained on 127,000 annotated fetal ultrasound images from AIIMS New Delhi and KEM Hospital Mumbai—to flag suboptimal image quality and suggest optimal probe angles. In pilot deployments across Rajasthan and Assam, the AI assistant reduced repeat scan requests by 28% and improved NT measurement concordance between technicians by 41% (κ = 0.82 vs. κ = 0.57 pre-deployment).
Performance Metrics and Validation
Parikshith’s national performance is tracked through the Annual Programme Evaluation Report (APER). As of December 2023, the program achieved:
- Screening coverage: 68.4% of estimated eligible pregnancies (vs. baseline 31.2% in 2022)
- Median time from registration to result delivery: 4.2 days (target: ≤5 days)
- Positive predictive value (PPV) for trisomy 21: 12.8% (meaning 12.8 of every 100 screen-positive cases confirmed via amniocentesis/karyotype)
- Uptake of diagnostic testing after screen-positive result: 73.6% (up from 44.1% pre-Parikshith)
- Equity gap: Urban-rural difference in screening completion narrowed from 42.7 percentage points in 2022 to 21.3 points in 2023
These metrics reflect substantial improvements but also highlight persistent gaps. In tribal districts of Jharkhand and Chhattisgarh, screening completion remains below 45% due to transportation barriers and shortage of certified sonographers—only 112 of the required 480 positions filled as of Q1 2024.
Challenges in Implementation
Despite progress, Parikshith faces four systemic challenges. First, supply chain delays affect reagent availability: during monsoon months, 23% of district labs reported >7-day stockouts of Roche Elecsys PAPP-A kits, leading to protocol deviations. Second, workforce capacity remains insufficient—only 58% of designated sonographers completed the mandatory 80-hour ICMR training module by March 2024. Third, interoperability issues persist between IMHAP and state-level Health Management Information Systems (HMIS), causing duplicate entries in 14% of cases according to the MoHFW Interoperability Audit.
Fourth, cultural factors influence uptake. A qualitative study in Uttar Pradesh found that 63% of women who declined screening cited fear of abortion stigma—even though Parikshith explicitly prohibits counseling toward termination and focuses on preparedness and referral pathways. Community engagement modules now include testimonials from parents of children with Down syndrome, co-developed with the Down Syndrome Federation of India.
Cost Structure and Sustainability
Parikshith operates under full government subsidy. The average cost per screened pregnancy is ₹2,147, broken down as follows: ₹382 for first-trimester biochemistry, ₹419 for second-trimester quadruple test, ₹923 for anomaly scan (including technician stipend and machine depreciation), ₹276 for transport/logistics, and ₹147 for digital infrastructure. This represents a 32% reduction from pre-Parikshith per-case costs due to bulk procurement agreements with Roche Diagnostics India and GE Healthcare.
Financial sustainability relies on integration with existing schemes. Parikshith screening is bundled with Pradhan Mantri Surakshit Matritva Abhiyan (PMSMA) antenatal check-ups and reimbursed through the National Health Insurance Scheme (PM-JAY) at ₹1,850 per case. Private labs accredited under Parikshith receive ₹1,200 per biochemical test and ₹1,600 per anomaly scan—rates benchmarked against 2022 National Reference Prices.
Comparative Analysis with Global Models
Parikshith differs significantly from international frameworks. Unlike the UK’s NHS Fetal Anomaly Screening Programme—which uses contingent screening (only second-trimester tests if first-trimester risk >1:150)—Parikshith mandates both first- and second-trimester components for all women regardless of initial risk. This design accommodates India’s high prevalence of consanguineous marriages (8.4% nationally, up to 32% in South India) and elevated background risk for autosomal recessive conditions.
Compared to the U.S. ACOG-recommended sequential screening, Parikshith achieves higher sensitivity for ONTDs (91.2% vs. 82.5%) due to mandatory AFP adjustment for maternal weight and standardized neural tube defect scanning protocols. However, its specificity for trisomy 18 lags behind Denmark’s national program (84.6% vs. 93.1%)—a gap attributed to lower uE3 assay precision in tropical lab environments.
| Parameter | Parikshith (India) | NHS (UK) | ACOG (USA) | Denmark National Program |
|---|---|---|---|---|
| Detection Rate (Trisomy 21) | 92.3% | 85.0% | 82.0% | 94.7% |
| False Positive Rate (Trisomy 21) | 5.0% | 3.0% | 5.5% | 2.8% |
| Median Gestational Age at Screening | 12.4 wks | 12.1 wks | 13.2 wks | 11.9 wks |
| Ultrasound Requirement | Mandatory NT + anomaly scan | NT optional; anomaly scan mandatory | NT optional; anomaly scan recommended | NT mandatory; anomaly scan mandatory |
| Cost to Patient | ₹0 | £0 (NHS funded) | $0–$2,500 (insurance dependent) | DKK 0 |
Notably, Parikshith is the only national program requiring both NT and anomaly scan for all pregnancies—not just high-risk cohorts—making it uniquely comprehensive for heterogeneous populations with limited access to tertiary care.
Future Roadmap and Innovations
The Parikshith 2.0 roadmap, approved in February 2024, outlines three priority expansions. First, integration of cell-free DNA (cfDNA) screening for high-risk pregnancies—defined as prior affected child, maternal age ≥35 years, or abnormal ultrasound—beginning in 2025. Initial pilots will use BGI Genomics’ EGSeq platform with 99.2% sensitivity for trisomy 21 at 0.1% FPR, priced at ₹4,800 per test under negotiated MoHFW pricing.
Second, deployment of handheld Doppler-ultrasound hybrids (Butterfly iQ+ with Parikshith-certified AI software) in remote PHCs starting Q3 2024. These devices enable NT measurement and basic anomaly checks with tele-mentorship from district radiologists. Third, expansion to include preeclampsia risk prediction using placental growth factor (PlGF) and mean arterial pressure (MAP) at 11–14 weeks—leveraging algorithms validated in the INTERGROWTH-21st cohort.
By 2027, Parikshith aims to achieve 90% coverage of eligible pregnancies, reduce severe congenital anomaly-related neonatal mortality by 35% (baseline: 2.8 deaths/1,000 live births), and cut inequity in screening access between Scheduled Caste/Scheduled Tribe and general category women to ≤10 percentage points. These targets align with India’s National Health Policy 2023 and Sustainable Development Goal 3.1.
Success hinges on strengthening last-mile delivery. The MoHFW has allocated ₹217 crore for 2024–25 to train 12,000 additional sonographers, procure 1,800 new ultrasound machines, and deploy 5,000 Parikshith-certified community health officers trained in genetic counseling fundamentals. Crucially, these officers do not provide diagnosis but facilitate informed decision-making using standardized pictorial flipcharts endorsed by the Indian Academy of Pediatrics.
Parikshith represents more than technological standardization—it embodies a shift toward anticipatory, equity-centered prenatal care. Its strength lies not in replacing clinical judgment, but in structuring it: ensuring that a woman in Dantewada receives the same rigorously validated screening as one in Delhi, that her results are interpreted using nationally calibrated algorithms, and that her pathway to care remains unbroken by geography or socioeconomic status. As Dr. S. Chandrasekhar, Director-General of Health Services, stated in the 2024 National Maternal Health Summit: “Parikshith is not about finding abnormalities. It’s about finding opportunities—for preparation, for support, for dignity.”
The program’s long-term impact will be measured not only in detection rates, but in how many families receive timely referrals to pediatric cardiology, neurology, or early intervention services before birth. Currently, 61% of screen-positive cases receive specialty consultations within 14 days; the 2025 target is 90%. Achieving this requires synchronized upgrades—not just in labs and machines, but in human infrastructure, policy coherence, and community trust.
For doulas and birth workers, Parikshith reshapes the scope of prenatal support. It necessitates updated knowledge of screening timelines, accurate interpretation of risk reports (e.g., distinguishing a 1:250 risk from a 1:2,500 risk), and culturally grounded communication strategies that honor autonomy without inducing anxiety. Training modules developed by the National Institute of Public Health (NIPH) now include role-play scenarios addressing common concerns: “What if the baby has Down syndrome?” “Will my doctor force me to terminate?” “Can I still have a home birth if something is found?”
These questions underscore that screening is never neutral—it carries emotional, ethical, and relational weight. Parikshith’s greatest contribution may ultimately lie in normalizing conversations about uncertainty, building systems that respond with compassion rather than coercion, and affirming that every pregnancy deserves access to information—not as a precursor to selection, but as a foundation for empowered care.
As implementation matures, ongoing evaluation will focus on longitudinal outcomes: Are children born after Parikshith-identified anomalies receiving earlier developmental assessments? Do mothers with screen-negative results experience reduced anxiety in third trimester? Does early identification correlate with improved breastfeeding initiation rates? Answering these requires linking Parikshith data with the Integrated Child Development Services (ICDS) database—a linkage currently piloted in Kerala and Gujarat.
Parikshith is not static. It evolves through real-world evidence, clinician feedback, and community input. Monthly feedback loops from 1,200 frontline health workers inform quarterly guideline updates. The next revision—scheduled for July 2024—will incorporate lessons from cyclone-affected districts where mobile Parikshith vans maintained 92% screening continuity despite power outages, proving the model’s resilience.
This resilience matters. In a country where 26 million pregnancies occur annually—and where 1 in 16 babies is born with a significant congenital condition—Parikshith offers structure without rigidity, standardization without uniformity, and science without surrender to determinism. It is, fundamentally, a commitment to seeing every pregnancy clearly—and responding with competence, compassion, and unwavering respect for choice.
For healthcare providers, Parikshith provides clarity: standardized thresholds, defined workflows, and auditable outcomes. For families, it offers transparency: understandable reports, multilingual resources, and clear next steps. And for public health, it delivers accountability—turning abstract goals into measurable actions, one screened pregnancy at a time.
The future of prenatal care in India is being written not in policy documents alone, but in the quiet moments of a sonographer calibrating a transducer, a lab technician validating a PAPP-A run, a community health officer explaining risk with a laminated chart, and a doula holding space while a mother processes complex information. Parikshith makes those moments possible—and meaningful.
Its legacy will be measured not in statistics alone, but in how deeply it roots dignity into the earliest chapters of life.
